tetano
Editor, Senior Moderator
Front Public Health
. 2021 Dec 17;9:801609.
doi: 10.3389/fpubh.2021.801609. eCollection 2021.
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up
Annachiara Coppola[SUP] 1 2 [/SUP], Carlo Buonerba[SUP] 1 [/SUP], Davide Cardinale[SUP] 1 [/SUP], Gabriella Lo Conte[SUP] 1 [/SUP], Donato Sansone[SUP] 1 [/SUP], Giuseppe Rofrano[SUP] 1 [/SUP], Sabato De Vita[SUP] 1 [/SUP], Maria Morgante[SUP] 3 [/SUP], Maria Triassi[SUP] 4 [/SUP], Luigi Atripaldi[SUP] 5 [/SUP], Gianfranco Brambilla[SUP] 6 [/SUP], Rocco Sabatino[SUP] 1 5 [/SUP], Andrea Pierri[SUP] 1 [/SUP], Daniela Pacella[SUP] 4 [/SUP], Antonio Pizzolante[SUP] 1 [/SUP], Biancamaria Pierri[SUP] 1 [/SUP], Veronica Ferrucci[SUP] 7 [/SUP], Massimo Zollo[SUP] 7 [/SUP], Mario Capasso[SUP] 7 [/SUP], Silvia Stringhini[SUP] 8 [/SUP], Paolo Antonio Ascierto[SUP] 9 [/SUP], Sante Roperto[SUP] 10 [/SUP], Pellegrino Cerino[SUP] 1 [/SUP]
Affiliations
Abstract
As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable for at least 9 months in a population-based study conducted in Wuhan, China, both in symptomatic and in asymptomatic individuals. In the mass screening campaign conducted in the town of Ariano Irpino (Avellino, Italy) in May, 2020, 5.7% (95% CI: 5.3-6-1) of the 13,444 asymptomatic citizens screened were positive for anti-nucleocapsid antibodies against SARS-CoV-2. Among these, 422 citizens were re-tested for anti SARS-CoV-2 antibodies in January, 2021 and/or in April, 2021 and enrolled in this longitudinal observational study. Median (interquartile range) age of the study cohort was 46 years (29-59), with 47 (11.1%) participants of minor age, while 217 (51.4%) participants were females. There was no evidence of re-infection in any of the subjects included. Presence of anti-nuclear antibodies antibodies (Elecysis, Roche) was reported in 95.7 and 93.7% of evaluable participants in January and April, 2021. Multiple logistic regression analysis used to explore associations between age, sex and seroprevalence showed that adults vs. minors had significantly lower odds of having anti-S1 antibodies (Biorad) both in January, 2021 and in April, 2021. Our findings showed that antibodies remained detectable at least 11.5 months after infection in >90% of never symptomatic cases. Further investigation is required to establish duration of immunity against SARS-CoV-2.
Keywords: SARS-CoV-2; antibody response; immunoassay; screening; seroprevalence.
. 2021 Dec 17;9:801609.
doi: 10.3389/fpubh.2021.801609. eCollection 2021.
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up
Annachiara Coppola[SUP] 1 2 [/SUP], Carlo Buonerba[SUP] 1 [/SUP], Davide Cardinale[SUP] 1 [/SUP], Gabriella Lo Conte[SUP] 1 [/SUP], Donato Sansone[SUP] 1 [/SUP], Giuseppe Rofrano[SUP] 1 [/SUP], Sabato De Vita[SUP] 1 [/SUP], Maria Morgante[SUP] 3 [/SUP], Maria Triassi[SUP] 4 [/SUP], Luigi Atripaldi[SUP] 5 [/SUP], Gianfranco Brambilla[SUP] 6 [/SUP], Rocco Sabatino[SUP] 1 5 [/SUP], Andrea Pierri[SUP] 1 [/SUP], Daniela Pacella[SUP] 4 [/SUP], Antonio Pizzolante[SUP] 1 [/SUP], Biancamaria Pierri[SUP] 1 [/SUP], Veronica Ferrucci[SUP] 7 [/SUP], Massimo Zollo[SUP] 7 [/SUP], Mario Capasso[SUP] 7 [/SUP], Silvia Stringhini[SUP] 8 [/SUP], Paolo Antonio Ascierto[SUP] 9 [/SUP], Sante Roperto[SUP] 10 [/SUP], Pellegrino Cerino[SUP] 1 [/SUP]
Affiliations
- PMID: 34976939
- PMCID: PMC8718636
- DOI: 10.3389/fpubh.2021.801609
Abstract
As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable for at least 9 months in a population-based study conducted in Wuhan, China, both in symptomatic and in asymptomatic individuals. In the mass screening campaign conducted in the town of Ariano Irpino (Avellino, Italy) in May, 2020, 5.7% (95% CI: 5.3-6-1) of the 13,444 asymptomatic citizens screened were positive for anti-nucleocapsid antibodies against SARS-CoV-2. Among these, 422 citizens were re-tested for anti SARS-CoV-2 antibodies in January, 2021 and/or in April, 2021 and enrolled in this longitudinal observational study. Median (interquartile range) age of the study cohort was 46 years (29-59), with 47 (11.1%) participants of minor age, while 217 (51.4%) participants were females. There was no evidence of re-infection in any of the subjects included. Presence of anti-nuclear antibodies antibodies (Elecysis, Roche) was reported in 95.7 and 93.7% of evaluable participants in January and April, 2021. Multiple logistic regression analysis used to explore associations between age, sex and seroprevalence showed that adults vs. minors had significantly lower odds of having anti-S1 antibodies (Biorad) both in January, 2021 and in April, 2021. Our findings showed that antibodies remained detectable at least 11.5 months after infection in >90% of never symptomatic cases. Further investigation is required to establish duration of immunity against SARS-CoV-2.
Keywords: SARS-CoV-2; antibody response; immunoassay; screening; seroprevalence.